Kontab50 mg+1 mg

Kontab is a proteolytic enzyme combination (a supplement/adjunct preparation) used mainly for the symptomatic relief of soft-tissue swelling and inflammation. Evidence for benefit is supportive but variable in strength across indications, so it is generally used as an adjunct to standard treatment rather than as a stand-alone therapy.

• Post-traumatic and post-surgical swelling/edema: Commonly used as adjunctive therapy to reduce soft-tissue swelling, bruising, and inflammation following minor surgery, dental extraction, episiotomy, or soft-tissue injury (sprains, contusions). Evidence is moderate and somewhat variable across trials.
• Inflammatory soft-tissue conditions: Used adjunctively for relief of localized inflammation and swelling associated with minor musculoskeletal injuries.
• Digestive/adjunct enzyme support: Occasionally used as an adjunct to support digestion of proteins, though this is a less well-established, more traditional use compared with the anti-inflammatory/anti-edema indication.

Kontab is not a substitute for definitive medical or surgical treatment of significant injury, infection, or active bleeding, and should be used alongside, not instead of, appropriate medical care.

Bromelain + Trypsin combines two proteolytic (protein-digesting) enzymes:

• Bromelain – a mixture of proteolytic enzymes extracted from the stem and fruit of the pineapple plant (Ananas comosus).
• Trypsin – a proteolytic enzyme, typically of pancreatic/animal or biotechnological origin, that breaks down proteins into smaller peptides.

Strengths and the exact ratio of bromelain to trypsin vary by brand and formulation; refer to the specific product label for exact strength per tablet/capsule.

Kontab is an oral proteolytic enzyme combination product. Bromelain and trypsin are both enzymes that break down proteins, and together they are marketed for their anti-inflammatory and anti-edema (anti-swelling) properties. They are proposed to work by breaking down fibrin and inflammatory mediators at the site of tissue injury, which may help reduce localized swelling, bruising, and inflammation and may modestly shorten recovery time after minor trauma or surgery.

Kontab is typically formulated as an oral tablet or capsule and is used as a short-course adjunct alongside standard medical or surgical care, rather than as a primary treatment.

Proteolytic (systemic) enzyme combination; anti-inflammatory / anti-edema agent

Mechanism of Action

Bromelain + Trypsin combines two proteolytic enzymes thought to act synergistically:

• Bromelain is a cysteine protease that has been shown in laboratory and clinical studies to reduce inflammatory mediators (e.g., bradykinin-related pathways), reduce fibrin deposition at injury sites, and exert a mild antiplatelet/fibrinolytic-type effect. It is also proposed to increase local tissue permeability, allowing better clearance of inflammatory exudate and faster resolution of edema and bruising.
• Trypsin is a serine protease that hydrolyzes peptide bonds in damaged/necrotic protein material and fibrin, helping to debride inflamed tissue and reduce the viscosity of inflammatory exudate, which is thought to complement bromelain's anti-edema effect.

Absorption of intact, enzymatically active protein following oral administration is limited (large protein molecules are subject to gastric and intestinal digestion), and the precise systemic pharmacokinetics of Bromelain + Trypsin are not fully characterized; a fraction of active enzyme is believed to be absorbed intact via specialized transport, which is proposed to underlie its systemic anti-inflammatory effects.

Kontab is usually taken orally. For anti-inflammatory/anti-edema use, it is often recommended to be taken on an empty stomach (e.g., 30–60 minutes before meals) to optimize systemic absorption of active enzyme, unless the product label specifically directs otherwise (e.g., some digestive-support formulations are taken with meals). Tablets/capsules should be swallowed whole with a full glass of water and not crushed or chewed unless the product is specifically designed for that. Always follow the specific brand's label instructions or the prescribing physician's advice.

Drug Interactions

• Anticoagulants and antiplatelet agents (e.g., warfarin, heparin, aspirin, clopidogrel): Bromelain has mild antiplatelet and fibrinolytic-type activity; concurrent use with Kontab may theoretically increase the risk of bleeding or bruising. Use with caution and under medical supervision; discontinue Kontab before scheduled surgery per standard perioperative supplement guidance.
• Certain antibiotics (e.g., amoxicillin, tetracyclines): Limited data suggest bromelain may increase the absorption/blood levels of some antibiotics when taken together. Clinical significance is generally considered minor, but concurrent use should be noted to the prescriber.
• Other herbal/supplement products with antiplatelet effects (e.g., ginkgo, garlic supplements): Additive bleeding-risk potential; use with caution.

Inform the prescriber of all medicines, supplements, and herbal products being taken before starting Kontab.

Kontab is generally well tolerated when used short-term at recommended doses. Reported side effects include:

• Gastrointestinal: Diarrhea, nausea, abdominal discomfort/dyspepsia (most common, usually mild and self-limiting).
• Allergic reactions: Skin rash, itching, urticaria, and, rarely, more severe hypersensitivity reactions, particularly in individuals with the pineapple/latex/pollen cross-reactivity allergy cluster (see Contraindications).
• Bleeding tendency: Increased bruising or bleeding risk, particularly at higher doses or with concurrent anticoagulant/antiplatelet use (see Interactions and Precautions).
• Other: Headache and dizziness have been reported infrequently.

Patients should seek medical advice if side effects are severe or persistent.

Pregnancy: Kontab should be avoided during pregnancy unless clearly needed and specifically advised by a physician, because bromelain has been associated with uterine-stimulant effects in some traditional and animal data at higher doses, and safety in human pregnancy has not been established. Use only if the potential benefit is judged by the treating physician to outweigh the potential risk.

Lactation: There is insufficient data on the excretion of bromelain or trypsin into human breast milk or their effects on the nursing infant. Kontab should be used during breastfeeding only if clearly needed and under medical supervision.

• Bleeding risk: Use Kontab with caution in patients on anticoagulant or antiplatelet therapy, or with any bleeding disorder, due to bromelain's reported mild antiplatelet/fibrinolytic-type activity (see Interactions and Contraindications).
• Perioperative use: Discontinue Kontab before any scheduled surgery or invasive procedure, per standard perioperative supplement guidance, because of the theoretical bleeding-risk concern.
• Allergy cross-reactivity: Use caution in patients with known allergy to pineapple, latex, wheat, celery, papain, or certain pollens, given the recognized cross-reactivity cluster with bromelain (see Contraindications).
• Antibiotic co-administration: Bromelain has been reported to modestly increase absorption of some antibiotics; clinical significance is generally minor but should be noted to the prescriber (see Interactions).
• Evidence limitations: The evidence for meaningful benefit in reducing post-surgical or post-traumatic swelling is moderate but variable across studies; Kontab should be used as an adjunct and does not replace appropriate medical or surgical evaluation and treatment of significant injury, infection, or bleeding.
• GI upset: Diarrhea and nausea can occur; taking with food (where the product label allows) may help reduce GI discomfort, though this may reduce systemic absorption for anti-inflammatory use.

Specific data on Kontab overdose in humans is limited. Excessive doses may increase the likelihood of gastrointestinal upset (nausea, vomiting, diarrhea, abdominal pain), allergic-type reactions, and an increased risk of bleeding or bruising. If an overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services rather than attempting home treatment. Management is supportive and symptomatic, guided by a physician.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: No well-established dose adjustment data exist for Kontab in renal impairment; use with caution and under medical supervision.
• Hepatic impairment: No well-established dose adjustment data exist for Kontab in hepatic impairment; use with caution and under medical supervision.
• Elderly: No specific dose adjustment is established for elderly patients, but caution is advised, particularly regarding bleeding risk if the patient is on anticoagulant/antiplatelet therapy (see Precautions).
• Children: Safety and efficacy of Kontab in pediatric patients have not been well established; use only under medical supervision (see Pediatric Uses).

Kontab is typically used as a short course, commonly around 5–10 days, for post-traumatic or post-surgical swelling, or as otherwise directed by the treating physician. It is not intended for indefinite or long-term continuous use without medical reassessment.

Proteolytic enzymes; Systemic enzyme therapy; Anti-inflammatory/anti-edema agents

Bromelain + Trypsin works through the combined proteolytic activity of bromelain (a cysteine protease) and trypsin (a serine protease). These enzymes are proposed to reduce inflammation and edema by breaking down fibrin deposits and inflammatory mediators at the site of tissue injury, improving local microcirculation and lymphatic drainage, and helping to debride damaged protein material. This is thought to accelerate resolution of swelling, bruising, and inflammation following minor trauma or surgery, and may modestly enhance the clearance of inflammatory exudate.

Safety and efficacy of Kontab in children have not been well established, and it is generally not recommended for routine use in pediatric patients outside of specific medical direction. If considered necessary, Kontab should be used in children only under the direct supervision of a physician, who will weigh potential benefits against the lack of robust pediatric safety data and the theoretical allergy/bleeding-risk concerns described above.